[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100160063":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":70,"centralContacts":74,"locations":83,"responsibleParty":458,"collaborators":33,"id":461,"slug":462,"hasResults":463,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":463,"sex":469,"minAge":33,"maxAge":470,"enrollmentInfo":471,"targetDuration":33,"studyType":474,"phases":475,"briefSummary":477,"conditions":478,"keywords":483,"overallStatus":110,"whyStopped":33,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":502},{"fullName":5,"class":6},"Medical University of Vienna","OTHER",[8,20],{"label":9,"type":6,"description":10,"interventionNames":11},"Standard Arm (Stratum II, III, IV, V)","Etoposid, cyclophosphamide, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt",[12,13,14,15,16,17,18,19],"Drug: Bevacizumab","Drug: Thalidomide","Drug: Celecoxib","Drug: Fenofibric acid","Drug: Etoposide","Drug: Cyclophosphamide","Drug: Etoposide phosphate","Drug: Cytarabine",{"label":21,"type":22,"description":23,"interventionNames":24},"Experimental arm (Stratum IV)","EXPERIMENTAL","Temozolomide, irinotecan, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt",[12,13,14,15,18,19,25,26],"Drug: Temozolomide (TMZ)","Drug: Irinotecan",[28,34,38,42,46,50,54,58,62,66],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","Bevacizumab","10mg\u002Fkg, intravenous (iv), biweekly, 1 year",[21,9],null,{"type":29,"name":35,"description":36,"armGroupLabels":37,"otherNames":33},"Thalidomide","3mg\u002Fkg, oral, daily, 1 year",[21,9],{"type":29,"name":39,"description":40,"armGroupLabels":41,"otherNames":33},"Celecoxib","50-400mg, oral bid, daily, 1 year",[21,9],{"type":29,"name":43,"description":44,"armGroupLabels":45,"otherNames":33},"Fenofibric acid","90mg\u002Fm2, oral, daily, 1 year",[21,9],{"type":29,"name":47,"description":48,"armGroupLabels":49,"otherNames":33},"Etoposide","35-50 mg\u002Fm2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year",[9],{"type":29,"name":51,"description":52,"armGroupLabels":53,"otherNames":33},"Cyclophosphamide","2.5mg\u002Fkg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year",[9],{"type":29,"name":55,"description":56,"armGroupLabels":57,"otherNames":33},"Etoposide phosphate","0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year",[21,9],{"type":29,"name":59,"description":60,"armGroupLabels":61,"otherNames":33},"Cytarabine","16-30mg, intrathecal, twice weekly for two weeks out of every four weeks, alternating with intrathecal etoposide phosphate, 1 year",[21,9],{"type":29,"name":63,"description":64,"armGroupLabels":65,"otherNames":33},"Temozolomide (TMZ)","Stratum IV; 150mg\u002Fm2, day 1-5 every four weeks",[21],{"type":29,"name":67,"description":68,"armGroupLabels":69,"otherNames":33},"Irinotecan","Stratum IV; 50mg\u002Fm2, day 1-5 every four weeks",[21],[71],{"name":72,"affiliation":5,"role":73},"Andreas Peyrl, MD","PRINCIPAL_INVESTIGATOR",[75,80],{"name":72,"role":76,"phone":77,"phoneExt":78,"email":79},"CONTACT","+43 1 40400","32320","andreas.peyrl@meduniwien.ac.at",{"name":81,"role":76,"phone":77,"phoneExt":78,"email":82},"Amedeo A Azizi, MD","amedeo.azizi@meduniwien.ac.at",[84,98,108,126,143,162,179,196,213,229,248,264,281,292,307,326,344,367,387,406,426,442],{"facility":85,"status":86,"city":87,"state":88,"zip":89,"country":90,"countryCode":91,"cosmosGeoPoint":92,"geoPoint":97,"contacts":33},"Ann & Robert H. Lurie Children's Hospital of Chicago","TERMINATED","Chicago","Illinois","60611-2605","United States","US",{"type":93,"coordinates":94},"Point",[95,96],-87.65005,41.85003,{"lat":96,"lon":95},{"facility":99,"status":86,"city":100,"state":101,"zip":102,"country":90,"countryCode":91,"cosmosGeoPoint":103,"geoPoint":107,"contacts":33},"Dana-Farber Cancer Institute and Boston Children's Hospital","Boston","Massachusetts","02215",{"type":93,"coordinates":104},[105,106],-71.05977,42.35843,{"lat":106,"lon":105},{"facility":109,"status":110,"city":111,"state":112,"zip":113,"country":90,"countryCode":91,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Helen DeVos Children's Hospital","RECRUITING","Grand Rapids","Michigan","48503",{"type":93,"coordinates":115},[116,117],-85.66809,42.96336,{"lat":117,"lon":116},[120,124],{"name":121,"role":76,"phone":122,"phoneExt":33,"email":123},"Rebecca Loret de Mola","616-267-0334","rebecca.loretdemola@helendevoschildrens.org",{"name":125,"role":73,"phone":33,"phoneExt":33,"email":33},"Rebecca Loret De Mola, MD",{"facility":127,"status":110,"city":128,"state":129,"zip":130,"country":90,"countryCode":91,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Dell Children's Medical Group SFC-HEM\u002FONC","Austin","Texas","78723",{"type":93,"coordinates":132},[133,134],-97.74306,30.26715,{"lat":134,"lon":133},[137,141],{"name":138,"role":76,"phone":139,"phoneExt":33,"email":140},"Ashley Ratcliffe","512-628-1900","aeRatcliff@ascension.org",{"name":142,"role":73,"phone":33,"phoneExt":33,"email":33},"Virginia Harrod, MD",{"facility":144,"status":110,"city":145,"state":33,"zip":146,"country":147,"countryCode":148,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Medical University of Graz","Graz","8036","Austria","AT",{"type":93,"coordinates":150},[151,152],15.44197,47.06733,{"lat":152,"lon":151},[155,160],{"name":156,"role":76,"phone":157,"phoneExt":158,"email":159},"Elisabeth Hulla-Gumbsch","+43 316 385","82686","elisabeth.hulla-gumbsch@klinikum-graz.at",{"name":161,"role":73,"phone":33,"phoneExt":33,"email":33},"Martin Benesch, MD",{"facility":163,"status":110,"city":164,"state":33,"zip":165,"country":147,"countryCode":148,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"Medical University of Innsbruck","Innsbruck","6020",{"type":93,"coordinates":167},[168,169],11.39454,47.26266,{"lat":169,"lon":168},[172,177],{"name":173,"role":76,"phone":174,"phoneExt":175,"email":176},"Yvonne Ennemoser, MSc","+43 512 504","23605","yvonne.ennemoser@tirol-kliniken.at",{"name":178,"role":73,"phone":33,"phoneExt":33,"email":33},"Roman Crazzolara, MD",{"facility":180,"status":110,"city":181,"state":33,"zip":182,"country":147,"countryCode":148,"cosmosGeoPoint":183,"geoPoint":187,"contacts":188},"Kepler Universitätsklinikum Med Campus IV","Linz","4020",{"type":93,"coordinates":184},[185,186],14.28611,48.30639,{"lat":186,"lon":185},[189,194],{"name":190,"role":76,"phone":191,"phoneExt":192,"email":193},"Martina Winkler","+43 5 7680 84","24302","martina.winkler@gespag.at",{"name":195,"role":73,"phone":33,"phoneExt":33,"email":33},"Georg Ebetsberger, MD",{"facility":197,"status":110,"city":198,"state":33,"zip":199,"country":147,"countryCode":148,"cosmosGeoPoint":200,"geoPoint":204,"contacts":205},"Salzburger Universitätsklinikum","Salzburg","5020",{"type":93,"coordinates":201},[202,203],13.04399,47.79941,{"lat":203,"lon":202},[206,211],{"name":207,"role":76,"phone":208,"phoneExt":209,"email":210},"Neil Jones, MD","+43 662 448257","759","n.jones@salk.at",{"name":212,"role":73,"phone":33,"phoneExt":33,"email":33},"Agnes Gamper, MD",{"facility":5,"status":110,"city":214,"state":33,"zip":215,"country":147,"countryCode":148,"cosmosGeoPoint":216,"geoPoint":220,"contacts":221},"Vienna","1090",{"type":93,"coordinates":217},[218,219],16.37208,48.20849,{"lat":219,"lon":218},[222,223,226,227],{"name":72,"role":76,"phone":77,"phoneExt":78,"email":79},{"name":224,"role":76,"phone":77,"phoneExt":78,"email":225},"Irene Slavc, MD","irene.slavc@meduniwien.ac.at",{"name":72,"role":73,"phone":33,"phoneExt":33,"email":33},{"name":224,"role":228,"phone":33,"phoneExt":33,"email":33},"SUB_INVESTIGATOR",{"facility":230,"status":110,"city":231,"state":33,"zip":232,"country":233,"countryCode":33,"cosmosGeoPoint":234,"geoPoint":238,"contacts":239},"University Hospital Brno","Brno","61300","Czechia",{"type":93,"coordinates":235},[236,237],16.60796,49.19522,{"lat":237,"lon":236},[240,244,246],{"name":241,"role":76,"phone":242,"phoneExt":33,"email":243},"Alexandra Martincekova, MD","+420532234755","Martincekova.Alexandra@fnbrno.cz",{"name":245,"role":73,"phone":33,"phoneExt":33,"email":33},"Jaroslav Sterba, MD",{"name":247,"role":228,"phone":33,"phoneExt":33,"email":33},"Zdenek Pavelka, MD",{"facility":249,"status":110,"city":250,"state":33,"zip":251,"country":233,"countryCode":33,"cosmosGeoPoint":252,"geoPoint":256,"contacts":257},"Motol University Hospital Prague","Prague","15006",{"type":93,"coordinates":253},[254,255],14.42076,50.08804,{"lat":255,"lon":254},[258,262],{"name":259,"role":76,"phone":260,"phoneExt":33,"email":261},"Klara Hruba","+42 0224436401","klara.hruba@fnmotol.cz",{"name":263,"role":73,"phone":33,"phoneExt":33,"email":33},"David Sumerauer, MD",{"facility":265,"status":110,"city":266,"state":33,"zip":267,"country":268,"countryCode":269,"cosmosGeoPoint":270,"geoPoint":274,"contacts":275},"University hospital Rigshospitalet","Copenhagen","2100","Denmark","DK",{"type":93,"coordinates":271},[272,273],12.56553,55.67594,{"lat":273,"lon":272},[276,280],{"name":277,"role":76,"phone":278,"phoneExt":33,"email":279},"Karsten Nysom, MD","+45 3545 0809","karsten.nysom@regionh.dk",{"name":277,"role":73,"phone":33,"phoneExt":33,"email":33},{"facility":282,"status":86,"city":283,"state":33,"zip":284,"country":285,"countryCode":286,"cosmosGeoPoint":287,"geoPoint":291,"contacts":33},"Centre Oscar Lambret","Lille","59037","France","FR",{"type":93,"coordinates":288},[289,290],3.05512,50.63391,{"lat":290,"lon":289},{"facility":293,"status":110,"city":294,"state":33,"zip":295,"country":285,"countryCode":286,"cosmosGeoPoint":296,"geoPoint":300,"contacts":301},"Centre Léon Bérard","Lyon","69373",{"type":93,"coordinates":297},[298,299],4.84789,45.74906,{"lat":299,"lon":298},[302,306],{"name":303,"role":76,"phone":304,"phoneExt":33,"email":305},"Pierre Leblond, MD","+33 4 78 78 28 28","pierre.leblond@ihope.fr",{"name":303,"role":73,"phone":33,"phoneExt":33,"email":33},{"facility":308,"status":110,"city":309,"state":33,"zip":310,"country":311,"countryCode":312,"cosmosGeoPoint":313,"geoPoint":317,"contacts":318},"Onkologisk-hematologisk seksjon Barneklinikken Haukeland universitetssjukehus","Bergen","5021","Norway","NO",{"type":93,"coordinates":314},[315,316],5.32415,60.39299,{"lat":316,"lon":315},[319,324],{"name":320,"role":76,"phone":321,"phoneExt":322,"email":323},"Ingrid Torsvik","+4705300","+4755975147","ingrid.kristin.torsvik@helse-bergen.no",{"name":325,"role":73,"phone":33,"phoneExt":33,"email":33},"Ingrid Torsvik, MD",{"facility":327,"status":110,"city":328,"state":33,"zip":329,"country":330,"countryCode":331,"cosmosGeoPoint":332,"geoPoint":336,"contacts":337},"Hospital Infantil Universitario Nino Jesus","Madrid","28009","Spain","ES",{"type":93,"coordinates":333},[334,335],-3.70256,40.4165,{"lat":335,"lon":334},[338,343],{"name":339,"role":76,"phone":340,"phoneExt":341,"email":342},"Alvaro Lassaletta, MD, PhD","+34 915 035938","377","alvaro.lassaletta@salud.madrid.org",{"name":339,"role":73,"phone":33,"phoneExt":33,"email":33},{"facility":345,"status":110,"city":346,"state":33,"zip":347,"country":348,"countryCode":349,"cosmosGeoPoint":350,"geoPoint":354,"contacts":355},"Sahlgrenska Universitetssjukhuset","Gothenburg","416 85","Sweden","SE",{"type":93,"coordinates":351},[352,353],11.96679,57.70716,{"lat":353,"lon":352},[356,360,363,365],{"name":357,"role":76,"phone":358,"phoneExt":33,"email":359},"Karin Fritzson","+46 31 343 58 65","karin.fritzson@vgregion.se",{"name":361,"role":76,"phone":358,"phoneExt":33,"email":362},"Anna Schröder- Håkansson","anna.schroder_hakansson@vgregion.se",{"name":364,"role":73,"phone":33,"phoneExt":33,"email":33},"Magnus Sabel, MD",{"name":366,"role":228,"phone":33,"phoneExt":33,"email":33},"Birgitta Lannering, Prof",{"facility":368,"status":110,"city":369,"state":33,"zip":370,"country":348,"countryCode":349,"cosmosGeoPoint":371,"geoPoint":375,"contacts":376},"Universitetssjukhuset Linköping","Linköping","581 85",{"type":93,"coordinates":372},[373,374],15.62157,58.41086,{"lat":374,"lon":373},[377,381,385],{"name":378,"role":76,"phone":379,"phoneExt":33,"email":380},"Birgitta Hellström","+46 10 103 13 54","birgitta.hellstrom@regionostergotland.se",{"name":382,"role":76,"phone":383,"phoneExt":33,"email":384},"Pernilla Augustsson","+46 10-103 13 50","pernilla.augustsson@regionostergotland.se",{"name":386,"role":73,"phone":33,"phoneExt":33,"email":33},"Irene Devenney, MD",{"facility":388,"status":110,"city":389,"state":33,"zip":390,"country":348,"countryCode":349,"cosmosGeoPoint":391,"geoPoint":395,"contacts":396},"Skånes universitetssjukhus","Lund","221 85",{"type":93,"coordinates":392},[393,394],13.19321,55.70584,{"lat":394,"lon":393},[397,401,404],{"name":398,"role":76,"phone":399,"phoneExt":33,"email":400},"Yvonne Håkansson","+46 46-17 80 64","Yvonne.Hakansson@skane.se",{"name":402,"role":76,"phone":399,"phoneExt":33,"email":403},"Simon Johansson","simon.johansson@skane.se",{"name":405,"role":73,"phone":33,"phoneExt":33,"email":33},"Helena Mörse, MD",{"facility":407,"status":110,"city":408,"state":33,"zip":409,"country":348,"countryCode":349,"cosmosGeoPoint":410,"geoPoint":414,"contacts":415},"Karolinska University Hospital","Stockholm","SE-171 76",{"type":93,"coordinates":411},[412,413],18.06871,59.32938,{"lat":413,"lon":412},[416,420,424],{"name":417,"role":76,"phone":418,"phoneExt":33,"email":419},"Carina Rinaldo","+46 8 517 701 51","carina.rinaldo@karolinska.se",{"name":421,"role":76,"phone":422,"phoneExt":33,"email":423},"Yvonne Copeland","+46 8 517 724 84","yvonne.copeland-wahlo@karolinska.se",{"name":425,"role":73,"phone":33,"phoneExt":33,"email":33},"Stefan Holm, MD",{"facility":427,"status":110,"city":428,"state":33,"zip":429,"country":348,"countryCode":349,"cosmosGeoPoint":430,"geoPoint":434,"contacts":435},"Norrlands Universitetssjukhus","Umeå","901 85",{"type":93,"coordinates":431},[432,433],20.25972,63.82842,{"lat":433,"lon":432},[436,440],{"name":437,"role":76,"phone":438,"phoneExt":33,"email":439},"Marita Wikström-Larsson","+46 90-785 02 44","Marita.Vikstrom.Larsson@vll.se",{"name":441,"role":73,"phone":33,"phoneExt":33,"email":33},"Mattias Mattsson",{"facility":443,"status":110,"city":444,"state":33,"zip":445,"country":348,"countryCode":349,"cosmosGeoPoint":446,"geoPoint":450,"contacts":451},"Akademiska sjukhuset","Uppsala","751 85",{"type":93,"coordinates":447},[448,449],17.63889,59.85882,{"lat":449,"lon":448},[452,456],{"name":453,"role":76,"phone":454,"phoneExt":33,"email":455},"Katarina Vallin","+46 18 611 34 94","katarina.vallin@akademiska.se",{"name":457,"role":73,"phone":33,"phoneExt":33,"email":33},"Anders Öberg, MD",{"type":73,"investigatorFullName":459,"investigatorTitle":460,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"Andreas Peyrl","MD","100160063","phase-2-antiangiogenic-therapy-for-children-with-recurrent-medulloblastoma-ependymoma-atrt-and-rare-cns-tumors-100160063",false,"NCT01356290","Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors","A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent\u002FProgressive Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors","MEMMAT","Inclusion criteria for patients Stratum I: Relapsed or progressive medulloblastoma - completed Stratum II: Relapsed or progressive ependymoma (at least one site of untreated recurrent disease) Stratum III: Relapsed or progressive ATRT (at least one site of untreated recurrent disease) Stratum IV: Relapsed or progressive medulloblastoma (at least one site of untreated recurrent disease) Stratum V: Relapsed or progressive CNS tumor of various histologies or patients with exclusion criteria or adult patients (explorative) Histological confirmation at diagnosis or relapse Stratum IV: Confirmation of the medulloblastoma group by methylation; IDAT (Intensity Data; raw data of methylation array) Female or male, aged from 0 to \\\u003C20 years (at time of original diagnosis) Participants must have normal organ and bone marrow function (ALT \\\u003C5x institutional upper limit of normal, creatinine \\\u003C1.5x institutional upper limit of normal for age, WBC \\>1000\u002Fmm3, platelets \\> 20,000\u002Fmm3. Patients with values less than WBC 2000\u002Fmm3 or platelets 50,000\u002Fmm3 will require initiation of treatment with etoposide and cyclophosphamide at a lower starting dose as defined within the protocol Karnofsky performance status ≥50. For infants and children less than 12 years of age, the Lansky play scale ≥50% will be used Written informed consent of patients and \u002F or legal guardian\n\nExclusion criteria for patients VP- or subdural peritoneal shunt dependency (can be included in Stratum V) Prior treatment with temozolomide\u002Firinotecan (can be included in Stratum V) Active infection, pregnancy or breast feeding Treatment for current relapse (surgery may be performed before MEMMAT treatment; patients with sites of disease not irradiated are still eligible for the protocol) Known hypersensitivity to any of the drugs in the protocol Active peptic ulcer Any significant cardiovascular disease not controlled by standard therapy e.g. systemic hypertension Anticipation of the need for major elective surgery during the course of the study treatment Any disease or condition that contraindicates the use of the study medication\u002Ftreatment or places the patient at an unacceptable risk of experiencing treatment-related complications Non-healing surgical wound A bone fracture that has not satisfactorily healed","ALL","19 Years",{"count":472,"type":473},232,"ESTIMATED","INTERVENTIONAL",[476],"PHASE2","Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of these modalities.\n\nAntiangiogenesis therapy has emerged as a new treatment option in solid malignancies. The frequent delivery of low doses of chemotherapy, referred to as metronomic or antiangiogenic chemotherapy, targets endothelial cells while reducing the toxicity associated with standard dose chemotherapy.\n\nThe aim of the study is to extend therapy options for children with recurrent or progressive medulloblastoma, ependymoma, ATRT, and CNS tumors of various histologies, for whom no known curative therapy exists, by prolonging survival while maintaining good quality of life.\n\nThe study will be conducted in independent strata. Stratum I (recurrent medulloblastoma): recently completed (Peyrl, 2023). Stratum II (recurrent ependymoma), III (recurrent ATRT) and V (recurrent CNS tumors of various histologies, patients with exclusion criteria and adult patients): The primary objective is to determine the response rate defined as the percentage of patients with complete response (CR), partial response (PR), stable disease (SD) or lack of recurrence at 6 months after start of antiangiogenic treatment. Stratum IV (recurrent medulloblastoma): To determine whether temozolomide, irinotecan, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt can increase the response rate after 6 months of treatment, compared with etoposid, cyclophosphamide, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt. Additionally, PFS, OS, toxicity, QoL, performance status, predictive and prognostic markers will be examined.\n\nIn stratum II and III, the study will follow an open label, single arm phase 2 design, and an open label randomized two-arm phase 2 design in Stratum IV, and the exploratory Stratum V.",[479,480,481,482],"Medulloblastoma Recurrent","Ependymoma Recurrent","ATRT Recurrent","Rare CNS Tumor Recurrent",[484,485,486,487,488,489,490,491,492],"Medulloblastoma","Ependymoma","ATRT","Relapse","Children","antiangiogenic","metronomic","intraventricular","Rare CNS tumor","2026-02-19",{"date":495,"type":496},"2026-02-23","ACTUAL",{"date":498,"type":496},"2014-04",{"date":500,"type":473},"2030-04",{"name":5,"class":6},22]